Growth Metrics

DiaMedica Therapeutics (DMAC) Change in Cash (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Change in Cash readings, the most recent being -$10.8 million for Q1 2026.

  • Quarterly Change in Cash fell 2372.25% to -$10.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Mar 2026, up 363.21% year-over-year, with the annual reading at $12.6 million for FY2025, 931.49% up from the prior year.
  • Change in Cash hit -$10.8 million in Q1 2026 for DiaMedica Therapeutics, down from $12.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $12.3 million in Q4 2025 and bottomed at -$10.8 million in Q1 2026.
  • Average Change in Cash over 5 years is $9470.6, with a median of -$436000.0 recorded in 2025.
  • The largest annual shift saw Change in Cash surged 12206.67% in 2023 before it crashed 2372.25% in 2026.
  • DiaMedica Therapeutics' Change in Cash stood at $2.0 million in 2022, then rose by 18.09% to $2.3 million in 2023, then plummeted by 147.99% to -$1.1 million in 2024, then surged by 1211.0% to $12.3 million in 2025, then plummeted by 187.48% to -$10.8 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Change in Cash are -$10.8 million (Q1 2026), $12.3 million (Q4 2025), and -$783000.0 (Q3 2025).